Trial Profile
Protocol IDN-6556-18 - A Post Treatment Follow-up Study for Liver Disease Subjects With or Without Liver Cirrhosis After Receiving Emricasan or Placebo
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2019
Price :
$35
*
At a glance
- Drugs Emricasan (Primary)
- Indications Liver disorders
- Focus Therapeutic Use
- Sponsors Conatus Pharmaceuticals
- 20 Nov 2019 Status changed from recruiting to discontinued.
- 29 Mar 2018 New trial record